Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
661-680 of 936 trials

Imaging α-Synuclein in the Brain: [18F]ACI-15916

We are testing a new imaging agent to see if it can help identify α-synuclein deposits in the brains of patients suspected of having related conditions. Healthy volunteers are also included to compare results.

Parkinson's DiseaseDementia with Lewy BodiesMultiple System AtrophySafety phase (I)Neurology

Advanced Cancers: AD-O51.4 Safety Study

We are evaluating the safety of a new investigational drug called AD-O51.4 for patients with advanced malignancies. This study aims to understand how well the drug is tolerated in this patient group.

Solid Tumor1-2 yearsSafety phase (I)Oncology

Heart Failure: Engineered Heart Tissue Treatment

We are studying a new type of heart tissue made from stem cells for patients with severe heart failure. The goal is to see if it is safe and effective in improving heart function and related symptoms.

Acute Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Optic Pathway Glioma: CHF6467 Eye Drops

We are studying the safety and effectiveness of a new eye drop treatment for children and young adults with optic pathway gliomas. This trial aims to see if it can improve their vision.

Optic Glioma≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyOphthalmology

V540A Vaccine Study in Healthy Adults

We are testing the V540A vaccine to see how it works in healthy adults. This study aims to evaluate its safety and effectiveness.

Human Papilloma Virus Infection1-2 yearsSafety phase (I)Infectious DiseasesOncology

Antibiotics in Cerebrospinal Fluid: A Study in Children

We are examining how well antibiotics work in the cerebrospinal fluid of children with an external ventricular drain. This research aims to improve treatment for infections in these patients.

Patients with External Ventricular Drain>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Meningiomas: ALpelisib and Trametinib Combination

We are testing a combination of two medications for patients with progressive, treatment-resistant meningiomas. The goal is to see if this approach can improve outcomes for these patients.

Meningiomas>2 yearsSafety phase (I)NeurologyOncology

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Primary Biliary Cholangitis: Golexanolone Study

We are testing a new medication, golexanolone, for individuals with primary biliary cholangitis who have significant fatigue and cognitive difficulties. The study aims to evaluate its safety and effects on daily life and cognitive function.

Primary Biliary Cholangitis3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesHepatologyInternal Medicine

Immune Activation: FLAMOD Aerosol Treatment

We are testing a new aerosol treatment to see if it safely activates the immune system. This study aims to understand how well it works in stimulating local immune responses.

Pneumonia6-12 monthsSafety phase (I)Infectious DiseasesPulmonology

Brain Health: 5-HT2A Receptor Study

We are investigating how changes in the 5-HT2A receptor may impact brain function. This research could help us understand treatments for various neurological conditions.

Healthy ParticipantsSafety phase (I)NeurologyPsychiatry

Solid Tumors: MK-0472 Study

We are investigating the effects of MK-0472 in people with solid tumors. This study aims to understand how well this treatment works compared to standard options.

Solid Tumors>2 yearsSafety phase (I)Oncology

HER2-Expressing Cancers: VIR-5818 and Pembrolizumab Study

We are testing a new treatment combining VIR-5818 with Pembrolizumab for patients with advanced or metastatic HER2-expressing cancers. This study aims to evaluate the safety and effects of this combination.

HER2-Positive Cancers>2 yearsSafety phase (I)Oncology

RR001 Gene Therapy for Locally Advanced Pancreatic Cancer

We are studying a new gene therapy combined with chemotherapy to see if it is safe and effective for patients with locally advanced pancreatic cancer. The trial will help determine the best dose and how well this treatment works.

Pancreatic CancerLocally Advanced Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: Eftilagimod Alpha Treatment

We are exploring a new treatment using eftilagimod alpha for patients with advanced solid tumors. The study looks at its safety and how it works with other therapies.

Non-Small Cell Lung Cancer (NSCLC)Urothelial CarcinomaMalignant Solid Tumor>2 yearsSafety phase (I)Oncology

Ifinatamab Deruxtecan for Metastatic Prostate Cancer

We are studying ifinatamab deruxtecan to see if it is safe and effective for men with metastatic castration-resistant prostate cancer. This trial will help us understand how well it works compared to other treatments.

Metastatic Castrate Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOphthalmology

Polycystic Kidney Disease: GSK4771261 Study

We are evaluating a new medication for safety and effectiveness in healthy individuals and those with autosomal dominant polycystic kidney disease. This study aims to understand how the drug works in different groups of people.

Polycystic Kidney Disease (Autosomal Dominant)1-2 yearsSafety phase (I)Internal MedicineNephrology

Hematologic Malignancies: HTLP Injection Study

We are testing a new injection to help adults with blood cancers recover their immune system after umbilical cord blood transplantation. This study aims to see if it is safe and effective for improving recovery.

Acute Myeloid Leukemia (AML)>2 yearsSafety phase (I)Hematology

Recurrent Brain Tumors in Children: Ultrasound Blood-Brain Barrier Study

We are evaluating a new ultrasound device to safely open the blood-brain barrier before chemotherapy in children with recurrent brain tumors. This study aims to see how well this method works and its effects on tumor progression.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesNeurologyOncologyPediatrics